Literature DB >> 1968085

Antiviral effect of 6-diazo-5-oxo-L-norleucine, antagonist of gamma-glutamyl transpeptidase, on replication of human parainfluenza virus type 2.

M Nishio1, M Tsurudome, H Bando, H Komada, Y Ito.   

Abstract

The antiviral effects of 6-diazo-5-oxo-L-norleucine (L-DON) on the replication of human parainfluenza virus type 2 (HPIV-2), mumps and vesicular stomatitis viruses were studied. L-DON suppressed growth of these viruses and, in particular, HPIV-2 in four cell types. L-DON was not toxic to the cells at the active dose and did not significantly inhibit cellular macromolecular synthesis. The L-DON-sensitive step of HPIV-2 replication was considered to be relatively early. The NP, P and M proteins were, although at a low level, clearly detectable in HPIV-2-infected Vero cells treated with L-DON, whereas the HN and F proteins were scarcely detected by either immunostaining or immunoprecipitation, indicating that L-DON mainly decreased the amounts of viral glycoproteins. Furthermore, Northern blot hybridization showed that secondary transcription of virus RNA was also inhibited.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968085     DOI: 10.1099/0022-1317-71-1-61

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  3 in total

1.  Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo-l-Norleucine in Mice with Alphavirus Encephalomyelitis.

Authors:  Sivabalan Manivannan; Victoria K Baxter; Kimberly L W Schultz; Barbara S Slusher; Diane E Griffin
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

2.  The homeostasis-maintaining metabolites from bacterial stress response to bacteriophage infection suppress tumor metastasis.

Authors:  Tianliang He; Min Jin; Chenxi Xu; Zhongjun Ma; Fufang Wu; Xiaobo Zhang
Journal:  Oncogene       Date:  2018-06-20       Impact factor: 9.867

3.  Inhibition in vitro of the replication of murine cytomegalovirus or reovirus type 3 by the glutamine analogue acivicin.

Authors:  D Keast; A R Vasquez
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.